{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T15:15:12Z","timestamp":1781709312964,"version":"3.54.5"},"publisher-location":"New York, NY","reference-count":28,"publisher":"Springer US","isbn-type":[{"value":"9781071627716","type":"print"},{"value":"9781071627723","type":"electronic"}],"license":[{"start":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T00:00:00Z","timestamp":1668816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T00:00:00Z","timestamp":1668816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"DOI":"10.1007\/978-1-0716-2772-3_12","type":"book-chapter","created":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T18:07:03Z","timestamp":1668794823000},"page":"197-208","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Knocking Down DUX4 in Immortalized Facioscapulohumeral Muscular Dystrophy Patient-Derived Muscle Cells"],"prefix":"10.1007","author":[{"given":"Kenji Rowel Q.","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,19]]},"reference":[{"key":"12_CR1","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s11910-016-0667-0","volume":"16","author":"LH Wang","year":"2016","unstructured":"Wang LH, Tawil R (2016) Facioscapulohumeral dystrophy. Curr Neurol Neurosci Rep 16:66. https:\/\/doi.org\/10.1007\/s11910-016-0667-0","journal-title":"Curr Neurol Neurosci Rep"},{"key":"12_CR2","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1017\/cjn.2015.311","volume":"43","author":"JK Mah","year":"2016","unstructured":"Mah JK, Korngut L, Fiest KM et al (2016) A systematic review and meta-analysis on the epidemiology of the muscular dystrophies. Can J Neurol Sci\/J Can Des Sci Neurol 43:163\u2013177. https:\/\/doi.org\/10.1017\/cjn.2015.311","journal-title":"Can J Neurol Sci\/J Can Des Sci Neurol"},{"key":"12_CR3","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.nmd.2006.06.008","volume":"16","author":"L Klinge","year":"2006","unstructured":"Klinge L, Eagle M, Haggerty ID et al (2006) Severe phenotype in infantile facioscapulohumeral muscular dystrophy. Neuromuscul Disord 16:553\u2013558. https:\/\/doi.org\/10.1016\/j.nmd.2006.06.008","journal-title":"Neuromuscul Disord"},{"key":"12_CR4","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/j.nmd.2017.09.007","volume":"27","author":"RJM Goselink","year":"2017","unstructured":"Goselink RJM, Voermans NC, Okkersen K et al (2017) Early onset facioscapulohumeral dystrophy \u2013 a systematic review using individual patient data. Neuromuscul Disord 27:1077\u20131083. https:\/\/doi.org\/10.1016\/j.nmd.2017.09.007","journal-title":"Neuromuscul Disord"},{"key":"12_CR5","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1126\/science.1189044","volume":"329","author":"RJLF Lemmers","year":"2010","unstructured":"Lemmers RJLF, van der Vliet PJ, Klooster R et al (2010) A unifying genetic model for facioscapulohumeral muscular dystrophy. Science 329:1650\u20131653. https:\/\/doi.org\/10.1126\/science.1189044","journal-title":"Science"},{"key":"12_CR6","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1146\/annurev-genom-083118-014933","volume":"20","author":"CL Himeda","year":"2019","unstructured":"Himeda CL, Jones PL (2019) The genetics and epigenetics of facioscapulohumeral muscular dystrophy. Annu Rev Genomics Hum Genet 20:265\u2013291. https:\/\/doi.org\/10.1146\/annurev-genom-083118-014933","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"12_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0378-1119(99)00267-X","volume":"236","author":"J Gabri\u00ebls","year":"1999","unstructured":"Gabri\u00ebls J, Beckers MC, Ding H et al (1999) Nucleotide sequence of the partially deleted D4Z4 locus in a patient with FSHD identifies a putative gene within each 3.3 kb element. Gene 236:25\u201332","journal-title":"Gene"},{"key":"12_CR8","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1093\/hmg\/3.8.1287","volume":"3","author":"JE Hewitt","year":"1994","unstructured":"Hewitt JE, Lyle R, Clark LN et al (1994) Analysis of the tandem repeat locus D4Z4 associated with facioscapulohumeral muscular dystropothhy. Hum Mol Genet 3:1287\u20131295. https:\/\/doi.org\/10.1093\/hmg\/3.8.1287","journal-title":"Hum Mol Genet"},{"key":"12_CR9","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/ng999","volume":"32","author":"RJLF Lemmers","year":"2002","unstructured":"Lemmers RJLF, de Kievit P, Sandkuijl L et al (2002) Facioscapulohumeral muscular dystrophy is uniquely associated with one of the two variants of the 4q subtelomere. Nat Genet 32:235\u2013236. https:\/\/doi.org\/10.1038\/ng999","journal-title":"Nat Genet"},{"key":"12_CR10","doi-asserted-by":"publisher","first-page":"R17\u201323","DOI":"10.1093\/hmg\/ddv237","volume":"24","author":"JE Hewitt","year":"2015","unstructured":"Hewitt JE (2015) Loss of epigenetic silencing of the DUX4 transcription factor gene in facioscapulohumeral muscular dystrophy: figure 1. Hum Mol Genet 24:R17\u201323. https:\/\/doi.org\/10.1093\/hmg\/ddv237","journal-title":"Hum Mol Genet"},{"key":"12_CR11","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/ng1262","volume":"35","author":"PGM van Overveld","year":"2003","unstructured":"van Overveld PGM, Lemmers RJFL, Sandkuijl LA et al (2003) Hypomethylation of D4Z4 in 4q-linked and non-4q-linked facioscapulohumeral muscular dystrophy. Nat Genet 35:315\u2013317. https:\/\/doi.org\/10.1038\/ng1262","journal-title":"Nat Genet"},{"key":"12_CR12","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/ng.2454","volume":"44","author":"RJLF Lemmers","year":"2012","unstructured":"Lemmers RJLF, Tawil R, Petek LM et al (2012) Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2. Nat Genet 44:1370\u20131374. https:\/\/doi.org\/10.1038\/ng.2454","journal-title":"Nat Genet"},{"key":"12_CR13","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/j.ajhg.2016.03.013","volume":"98","author":"ML van den Boogaard","year":"2016","unstructured":"van den Boogaard ML, Lemmers RJLF, Balog J et al (2016) Mutations in DNMT3B modify epigenetic repression of the D4Z4 repeat and the penetrance of facioscapulohumeral dystrophy. Am J Hum Genet 98:1020\u20131029. https:\/\/doi.org\/10.1016\/j.ajhg.2016.03.013","journal-title":"Am J Hum Genet"},{"key":"12_CR14","doi-asserted-by":"publisher","first-page":"e2441","DOI":"10.1212\/WNL.0000000000009617","volume":"94","author":"K Hamanaka","year":"2020","unstructured":"Hamanaka K, \u0160ikrov\u00e1 D, Mitsuhashi S et al (2020) Homozygous nonsense variant in LRIF1 associated with facioscapulohumeral muscular dystrophy. Neurology 94:e2441\u2013e2447. https:\/\/doi.org\/10.1212\/WNL.0000000000009617","journal-title":"Neurology"},{"key":"12_CR15","doi-asserted-by":"publisher","first-page":"729","DOI":"10.3390\/ijms21030729","volume":"21","author":"KRQKRQ Lim","year":"2020","unstructured":"Lim KRQKRQ, Nguyen Q, Yokota T (2020) DUX4 signalling in the pathogenesis of facioscapulohumeral muscular dystrophy. Int J Mol Sci 21:729. https:\/\/doi.org\/10.3390\/ijms21030729","journal-title":"Int J Mol Sci"},{"key":"12_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.642858","volume":"12","author":"KRQ Lim","year":"2021","unstructured":"Lim KRQ, Yokota T (2021) Genetic approaches for the treatment of facioscapulohumeral muscular dystrophy. Front Pharmacol 12:642858. https:\/\/doi.org\/10.3389\/fphar.2021.642858","journal-title":"Front Pharmacol"},{"key":"12_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0026820","volume":"6","author":"C Vanderplanck","year":"2011","unstructured":"Vanderplanck C, Ansseau E, Charron S et al (2011) The FSHD atrophic myotube phenotype is caused by DUX4 expression. PLoS One 6:e26820. https:\/\/doi.org\/10.1371\/journal.pone.0026820","journal-title":"PLoS One"},{"key":"12_CR18","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1093\/hmg\/ddw015","volume":"25","author":"A-C Marsollier","year":"2016","unstructured":"Marsollier A-C, Ciszewski L, Mariot V et al (2016) Antisense targeting of 3\u2032 end elements involved in DUX4 mRNA processing is an efficient therapeutic strategy for facioscapulohumeral dystrophy: a new gene-silencing approach. Hum Mol Genet 25:1468\u20131478. https:\/\/doi.org\/10.1093\/hmg\/ddw015","journal-title":"Hum Mol Genet"},{"key":"12_CR19","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1038\/mt.2016.111","volume":"24","author":"JC Chen","year":"2016","unstructured":"Chen JC, King OD, Zhang Y et al (2016) Morpholino-mediated knockdown of DUX4 toward facioscapulohumeral muscular dystrophy therapeutics. Mol Ther 24:1405\u20131411. https:\/\/doi.org\/10.1038\/mt.2016.111","journal-title":"Mol Ther"},{"key":"12_CR20","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3390\/genes8030093","volume":"8","author":"E Ansseau","year":"2017","unstructured":"Ansseau E, Vanderplanck C, Wauters A et al (2017) Antisense oligonucleotides used to target the DUX4 mRNA as therapeutic approaches in faciosscapulohumeral muscular dystrophy (FSHD). Genes (Basel) 8:93. https:\/\/doi.org\/10.3390\/genes8030093","journal-title":"Genes (Basel)"},{"key":"12_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-0716-0771-8_1","volume-title":"Gapmers methods protoc","author":"KRQ Lim","year":"2020","unstructured":"Lim KRQ, Yokota T (2020) Invention and early history of gapmers. In: Yokota T, Maruyama R (eds) Gapmers methods protoc. Springer, pp 3\u201319"},{"key":"12_CR22","doi-asserted-by":"publisher","first-page":"16509","DOI":"10.1073\/pnas.1909649117","volume":"117","author":"KRQ Lim","year":"2020","unstructured":"Lim KRQ, Maruyama R, Echigoya Y et al (2020) Inhibition of DUX4 expression with antisense LNA gapmers as a therapy for facioscapulohumeral muscular dystrophy. Proc Natl Acad Sci 117:16509\u201316515. https:\/\/doi.org\/10.1073\/pnas.1909649117","journal-title":"Proc Natl Acad Sci"},{"key":"12_CR23","doi-asserted-by":"publisher","unstructured":"Lim KRQ, Bittel A, Maruyama R et al (2020) DUX4 transcript knockdown with antisense 2\u2032-o-methoxyethyl gapmers for the treatment of facioscapulohumeral muscular dystrophy. Mol Ther. https:\/\/doi.org\/10.1016\/j.ymthe.2020.10.010","DOI":"10.1016\/j.ymthe.2020.10.010"},{"key":"12_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1001181","volume":"6","author":"L Snider","year":"2010","unstructured":"Snider L, Geng LN, Lemmers RJLF et al (2010) Facioscapulohumeral dystrophy: incomplete suppression of a retrotransposed gene. PLoS Genet 6:e1001181. https:\/\/doi.org\/10.1371\/journal.pgen.1001181","journal-title":"PLoS Genet"},{"key":"12_CR25","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/j.1582-4934.2012.01647.x","volume":"17","author":"A Tassin","year":"2013","unstructured":"Tassin A, Laoudj-Chenivesse D, Vanderplanck C et al (2013) DUX4 expression in FSHD muscle cells: how could such a rare protein cause a myopathy? J Cell Mol Med 17:76\u201389. https:\/\/doi.org\/10.1111\/j.1582-4934.2012.01647.x","journal-title":"J Cell Mol Med"},{"key":"12_CR26","doi-asserted-by":"publisher","first-page":"8304","DOI":"10.3390\/molecules20058304","volume":"20","author":"SN Pandey","year":"2015","unstructured":"Pandey SN, Khawaja H, Chen Y-W (2015) Culture conditions affect expression of DUX4 in FSHD myoblasts. Molecules 20:8304\u20138315. https:\/\/doi.org\/10.3390\/molecules20058304","journal-title":"Molecules"},{"key":"12_CR27","doi-asserted-by":"publisher","first-page":"4661","DOI":"10.1093\/hmg\/ddt314","volume":"22","author":"GJ Block","year":"2013","unstructured":"Block GJ, Narayanan D, Amell AM et al (2013) Wnt\/\u03b2-catenin signaling suppresses DUX4 expression and prevents apoptosis of FSHD muscle cells. Hum Mol Genet 22:4661\u20134672. https:\/\/doi.org\/10.1093\/hmg\/ddt314","journal-title":"Hum Mol Genet"},{"key":"12_CR28","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/2044-5040-1-12","volume":"1","author":"G Stadler","year":"2011","unstructured":"Stadler G, Chen JCJ, Wagner K et al (2011) Establishment of clonal myogenic cell lines from severely affected dystrophic muscles \u2013 CDK4 maintains the myogenic population. Skelet Muscle 1:12. https:\/\/doi.org\/10.1186\/2044-5040-1-12","journal-title":"Skelet Muscle"}],"container-title":["Methods in Molecular Biology","Muscular Dystrophy Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-2772-3_12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T07:07:30Z","timestamp":1677654450000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-2772-3_12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,19]]},"ISBN":["9781071627716","9781071627723"],"references-count":28,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-2772-3_12","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,19]]},"assertion":[{"value":"19 November 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}